Innoviva Inc
NASDAQ:INVA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.4
20.32
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Innoviva Inc
Innoviva Inc
Cash from Investing Activities
Innoviva Inc
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innoviva Inc
NASDAQ:INVA
|
Cash from Investing Activities
-$53.5m
|
CAGR 3-Years
40%
|
CAGR 5-Years
14%
|
CAGR 10-Years
1%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Investing Activities
-$18.5B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Investing Activities
-$22.5B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Investing Activities
-$3.8B
|
CAGR 3-Years
31%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Investing Activities
-$6.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Investing Activities
-$10.3B
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-13%
|
|
Innoviva Inc
Glance View
In the heart of Silicon Valley, Innoviva Inc. has carved out a niche within the pharmaceutical landscape, balancing the art of innovation with the demands of modern healthcare economics. Initially emerging as a dynamic player in drug development, Innoviva made a strategic pivot to focus on the monetization and management of its royalties and collaborations. The company's primary revenue stream flows from partnerships with GlaxoSmithKline (GSK), stemming from co-developed respiratory treatments like the inhaled medications Trelegy and Anoro Ellipta. These partnerships provide Innoviva with steady royalty income based on product sales, allowing it to operate with a lean but effective business model, focusing on maximizing value from its existing assets rather than pursuing the expensive and risky path of drug discovery and development. Beyond merely basking in the comfort of predictable cash flows, Innoviva has tactically reinvested its earnings to fuel further growth and diversification. The company has been channeling resources into acquiring new assets and entering joint ventures that align with its core expertise and long-term vision. This approach not only broadens its portfolio but also hedges against the inherent risks associated with dependency on a limited number of revenue sources. By leveraging its financial strength and strategic partnerships, Innoviva has positioned itself as a nimble player in the pharmaceutical sector, adept at extracting maximum value through prudent financial management and strategic foresight.
See Also
What is Innoviva Inc's Cash from Investing Activities?
Cash from Investing Activities
-53.5m
USD
Based on the financial report for Sep 30, 2024, Innoviva Inc's Cash from Investing Activities amounts to -53.5m USD.
What is Innoviva Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
1%
Over the last year, the Cash from Investing Activities growth was 24%. The average annual Cash from Investing Activities growth rates for Innoviva Inc have been 40% over the past three years , 14% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
